AIMT

$34.49
+$0.00 (+0.0%)
Closing price October 13, 2020
The prize for Nestle in its acquisition of Aimmune Therapeutics is Palforzia, the world’s first treatment for a food allergy.
Consumer products giant Nestlé has agreed to acquire Aimmune Therapeutics, maker of a peanut-allergy treatment. The deal is valued at $2.6 billion, including Nestlé's existing stake Aimmune.
Monday's top analyst calls included AbbVie, AES, AT&T, Boeing, Carnival, CME, Coca-Cola, Comcast, Honeywell, Lululemon Athletica, Netflix, Shopify, Starbucks and Twitter.